Ascletis Pharma Debuts in Hong Kong

The video discusses the significance of the first biotech company listing on the Hong Kong Stock Exchange, highlighting a new drug approval by China FDA. It examines IPO subscription trends, noting a reliance on institutional buyers due to low retail demand. The outlook for Hong Kong's IPO market is considered, with a focus on attracting more listings. Future biotech listings and the pricing of China Tower are also discussed, with potential implications for the market.

How many biotech companies have filed for a listing in Hong Kong as mentioned in the text?

What is the significance of the pricing of China Tower in the context of the Hong Kong market?